Madhu Kumar

The markets are entering somewhat uncertain territory, as the S&P 500 recently experienced its 39th correction since the beginning of 1950 due to a combination of the omicron fears, and the anticipation of the Fed raising rates to curb the surge of inflation. This has led to...

The COVID-19 virus has sent the market and the global economy into a tailspin. The Organisation for Economic Co-operation and Development slashed its global growth forecast for 2020 Monday by 0.5 points to 2.5% versus already-weak 2.9% growth in 2019. Global banks have begun talking up the...

Intellia Therapeutics Inc’s (NASDAQ: NTLA) gene editing drug seems to have the potential to disrupt the treatment of hereditary transthyretin amyloidosis, according to Baird. The Analyst Madhu Kumar initiated coverage of Intellia Therapeutics with an Outperform rating and $23 price target....

Assembly Biosciences Inc (NASDAQ: ASMB) shares have shed over one-fourth of their value since late September, creating an opportunity to buy the dip, B. Riley FBR said Monday.  The Analyst Analyst Madhu Kumar upgraded shares of Assembly Biosciences from Neutral to Buy and reiterated a $42...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) stock tanked 15 percent Thursday after the company announced a new $3.7-billion deal to license its ARO-HBV treatment for chronic hepatitis B to Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Pharmaceuticals. Investors clearly weren’t...

Arbutus Biopharma Corp (NASDAQ: ABUS) stock has gained 80 percent since the turn of the year, and B. Riley FBR dropped its bullish stance Friday in the wake of the rally.   The Analyst B. Riley FBR's Madhu Kumar downgraded Arbutus Biopharma from Buy to Neutral with an unchanged $...

Uniqure NV (NASDAQ: QURE), a gene therapy company that focuses on severe unmet medical needs, could "dominate" the space with its AMT-061 therapy, according to B. Riley FBR. The Analyst B. Riley FBR's Madhu Kumar initiated coverage of Uniqure with a Buy rating and $50 price target....

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) lost a sell-side bull Tuesday, with a B. Riley FBR analyst praising the company's pipeline but concluding the biotech's positives are priced into the stock. The Analyst B. Riley FBR's Madhu Kumar downgraded Deciphera from Buy to Neutral. The...

A little more than a year after its initial public offering, Tocagen Inc (NASDAQ: TOCA) has traded down 26 percent, but experts are decidedly bullish on the company’s prospects and potential valuation. The Rating B Riley analyst Madhu Kumar initiated coverage on Tocagen with a Buy rating...

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) continued to decline after Pfizer Inc. (NYSE: PFE) reported its transthyretin stabilizer Vyndaqel met primary Phase 3 endpoints Thursday. However, B Riley FBR considers the ostensible competitor’s victory a positive for Alnylam. The Rating...

An optimistic trial outlook on Clementia Therapeutics, Inc. (NASDAQ: CMTA)’s palovarotene in FOP patients could give the pharmaceutical company a leg up in an unmet market for the treatment of a rare disease, according to B. Riley FBR. The Analyst Madhu Kumar of B. Riley FBR initiated...

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA), a biotechnology company developing GalXC RNAi platforms for various diseases, has seen its stock soar 140 percent over the past six months. But a combination of good news and bad news should leave investors on the sidelines, according to B. Riley FBR....

Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) announced Tuesday that the U.S. Food and Drug Administration accepted a New Drug Application for eravacycline, an antibiotic for complicated intra-abdominal infection, for priority review. Traders initially reacted positively, and so did analysts. The...

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH)’s kinase switch control platform has largely gone unnoticed on the Street. The nascent portfolio caught an analyst's attention this week.  The Rating B Riley analyst Madhu Kumar initiated coverage on Deciphera with a Buy rating and $43...

On both an absolute and relative basis, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)’s pipeline is a winner. “We have conviction that Alnylam’s hATTR franchise will dominate that of Ionis,” FBR analyst Madhu Kumar wrote in a Monday note. Ionis Pharmaceuticals Inc (NASDAQ:...